| NEWS | BIOGRAPHIES | EVENTS | INSIDE FIS | MARKETING | MEDICAL | |
CROSS-COUNTRY
SKI JUMPING
NORDIC COMBINED
ALPINE SKIING
FREESTYLE SKIING
SNOWBOARD
OTHERS
SPEED SKIING
GRASS SKIING
TELEMARK
MASTERS
CALENDAR
RESULTS
STATISTICS
LIVE TIMING
FIS HISTORY
| FIS Anti-Doping >> Medical / Anti-Doping Rules >> Therapeutic Use Exemptions (TUE) |
Information letter
Information letter TUE - Vancouver 2010
Therapeutic Use Exemptions (TUE)
WADA International Standard for Therapeutic Use Exemption 2010
FIS Therapeutic Use Exemption form (to be completed electronically)
Declaration of Use (DoU)
Changes in compliance with the WADA Code 2009
-
In compliance with the 2009 Code, references to Abbreviated TUEs have been removed.
-
In accordance with the International Standard for Therapeutic Use Exemptions, a Declaration of Use must be completed by the Athlete for the administration of glucocorticosteroids by intraarticular, periarticular, perintendinous, epidural, intradermal and inhalation routes.
-
No TUE or declaration of use is required for topical administration of glucocorticosteroids.
Changes from 1st January 2010 on:
-
The use of salbutamol and salmeterol by inhalation no longer requires a TUE but a Declaration of Use must be completed.
Requirements for use of the beta-2-agonists formoterol and terbutaline
Current FIS/IOC Anti-Doping requirements for use of the beta-2 agonists formoterol and terbutaline
For any questions please contact FIS Anti-Doping antidoping@fisski.com